ClinicalTrials.gg
Sign In
Status unknownNCT03322189Updated Jan 23, 2019

Pharmacogenomics Results Affect Patients' Plan of Care and Changes in Medication Prescription(s)

An observational study in Pharmacogenomic, sponsored by Data Collection Analysis Business Management. Status unknown at 1 site in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-23.

Sponsored by Data Collection Analysis Business Management · Observational

The sponsor has not verified this record recently (last verified Jan 2019), so the status shown — last known as Enrolling by invitation — may be out of date.
Study type
Observational
Model
Other
Time perspective
Other
Enrollment
200
Ages
18 Years to 64 Years
Sex
All
01

Study summary

Current providers' standard operating procedures on pharmacogenomic testing patients

Read the detailed description

The general design of this study is collecting data and reviewing Principal Investigators' Standard Operating Procedures on Pharmacogenomic testing and changes made to their specific SOP.

02

Conditions studied

  • Pharmacogenomic
03

In context

Lead sponsor

Data Collection Analysis Business Management is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Current standard operating procedures for providers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be a Medical Practitioner

    • Medical Doctor (MD)
    • Doctor of Osteopathic (DO)
    • Physician Assistant (PA)
    • Advanced Practice Registered Nurse (APRN)
    • Nurse Practioner (NP)
  • Must have a current standard operating procedure that includes obtaining/reviewing medical history.

Exclusion criteria

Exclusion Criteria:

  • Government-funded insurance data cannot be included in the study.
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
200 participants (estimated)
Patient registry
No

Interventions

  • Geneticpharmacogenomic

    Standard Operating Procedures on Pharmacogenomic testing and changes made to specific SOP

06

What researchers measure

Primary outcomes

  1. Provider Structures and Processes

    Plan of Care Changes due to Pharmacogenomic testing. Provider based observational survey system on the health and well-being of patients and populations

    Time frame: 36 months

07

Study locations

1 site
  • DCABM
    Land O' Lakes, Florida 33558, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2017 (actual). Primary completion is estimated for Mar 2020, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2017
First posted
Oct 26, 2017
StartActual
Mar 22, 2017
Primary completionEst.
Mar 22, 2020
CompletionEst.
Apr 1, 2020
Last update
Jan 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03322189
Lead sponsor
Data Collection Analysis Business Management
Collaborators
PAS Research Services
Responsible party
Sponsor
First posted
Oct 26, 2017
Start date
Mar 22, 2017
Primary completion
Mar 22, 2020 (estimated)
Completion
Apr 1, 2020 (estimated)
Last update
Jan 23, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Data Collection Analysis Business Management

Start the discussion